KRAS and neoplasm: Our results are supported by a recent analysis of the NCIC CTG CO.17 trial (that investigated cetuximab plus best supportive care (BSC) versus BSC alone), which reported less striking cetuximab-induced effects in patients with KRAS codon 12/13 wild-type, right-sided tumors as compared with patients bearing a left-sided tumor (Brule et al. 2013).